Health officials on May 27 announced they’re narrowing recommendations for COVID-19 vaccinations.
The latest versions of the vaccines were cleared by the Food and Drug Administration in 2024 without any clinical data. The CDC previously advised pregnant women and children to receive at least one dose of the currently available formulations of the shots, even if they had previously been vaccinated.
Those recommendations came “despite the lack of any clinical data to support the repeat booster strategy in children,” Kennedy said.
Dr. Jay Bhattacharya, director of the National Institutes of Health, said in the video: “That ends today. It’s common sense, and it’s good science.”
Dr. Marty Makary, the FDA’s commissioner, added: “There’s no evidence healthy kids need it today, and most countries have stopped recommending it for children.”
The CDC, FDA, and National Institutes of Health are all part of the Department of Health and Human Services (HHS), which Kennedy heads.
It’s not clear if the CDC was involved in the decision.
A query to the CDC was answered by the HHS. A spokesperson for HHS told The Epoch Times in an email that “as part of the Trump administration’s commitment to common sense, the COVID-19 vaccine will be removed from the CDC’s recommended immunization schedule” and “HHS and the CDC remain committed to gold standard science and to ensuring the health and well-being of all Americans—especially our nation’s children—using common sense.”
Just 13 percent of children and 14 percent of pregnant women have taken one of the vaccines since the fall of 2024, according to CDC data.
The panel, which provides vaccine advice to the CDC, was expected to discuss the matter further and hold a formal vote establishing its position during its next meeting, in June.
Some others criticized the move.
While people can still receive vaccines that are not on the schedules, insurers typically do not cover those immunizations. Jha said Medicaid likely would not either.
For everyone else, vaccine manufacturers would have to present clinical trial data showing the vaccines prevented symptomatic COVID-19, the officials said.
The companies could, however, maintain the current formulations, the FDA said.
The currently available Pfizer and Moderna shots target KP.2. The Novavax vaccine targets JN.1.